デフォルト表紙
市場調査レポート
商品コード
1193135

オランザピン市場:用途別、投与経路別、流通チャネル別:世界の機会分析および産業予測、2021-2031年

Olanzapine Market By Application, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 229 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.66円
オランザピン市場:用途別、投与経路別、流通チャネル別:世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 229 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オランザピンは非定型抗精神病薬で、主に統合失調症や双極性障害の治療に使用されます。

錠剤、注射剤、崩壊錠の形態で提供されています。ドパミンとセロトニンのバランスをとり、認知、気分、行動を強化します。オランザピンは、13歳以上の成人および10代の若者における、思考障害や奇妙な考え、生活への興味の喪失、強い感情や不適切な感情を引き起こす精神疾患である統合失調症の症状の治療に使用されます。また、13歳以上の成人および青年期において、躁病、悲哀、その他の異常な気分のエピソードを生じる躁うつ病である双極性障害の治療にも使用されています。

世界保健機関(WHO)は、加盟国のメンタルヘルスを促進し、精神障害を予防するために、メンタルヘルス行動計画を推奨しています。また、WHOが発表した主要な事実によると、全世界で推定3億人がうつ病に、6,000万人が双極性障害に罹患していると言われています。不安障害は、子どもから大人までが罹患する最も一般的な精神疾患です。4400万人のアメリカの大人が不安障害の影響を受けていると評価されています。不安障害は非常に治療しやすい疾患であるにもかかわらず、不安障害に苦しむ人々の約3分の1が治療を受けているに過ぎません。したがって、この市場は主に精神疾患の有病率の上昇によって牽引されていると考えられます。

オランザピンの世界市場の成長は、主に統合失調症の世界の有病率の上昇によってもたらされます。例えば、世界保健機関(WHO)によると、2022年1月、統合失調症は世界で約2,400万人、300人に1人(0.32%)が罹患していると言われています。また、衛生管理や予防措置の欠如による病院内感染(HAI)の増加が、市場成長の主な要因となっています。さらに、精神障害者向け診療所の増加や医療インフラの整備も、市場拡大に寄与しています。しかし、オランザピンの高価格と副作用が市場成長の妨げになっています。逆に、主要なプレーヤーによる市場におけるオランザピンの製品承認の増加と新興経済諸国における高い成長の可能性は、市場プレーヤーに有利な機会を提供すると予想されます。例えば、2021年6月、世界のバイオ医薬品会社であるAlkermes plc.は、成人の統合失調症の治療および成人の双極I型障害の治療として、維持単剤療法として、またはリチウムまたはバルプロ酸の補助療法として躁または混合エピソードの急性治療としてLYBALVI(オランザピンおよびサミドールファン)の米国食品医薬品局(FDA)を取得しました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19市場への影響分析

第4章 オランザピン市場:用途別

  • 概要
    • 市場規模および予測
  • 統合失調症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 双極性障害
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第5章 オランザピン市場:投与経路別

  • 概要
    • 市場規模および予測
  • 経口
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 非経口
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第6章 オランザピン市場:流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院薬局
    • 主な市場動向、成長要因と機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • ドラッグストア、小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • オンラインプロバイダー
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第7章 オランザピン市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米の市場規模・予測:アプリケーション別
    • 北米市場規模・予測:投与経路別
    • 北米市場規模・予測:流通チャネル別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:アプリケーション別
    • 欧州市場規模・予測:投与経路別
    • 欧州市場規模・予測:流通チャネル別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:アプリケーション別
    • アジア太平洋地域の市場規模・予測:投与経路別
    • アジア太平洋地域の市場規模・予測:流通チャネル別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:アプリケーション別
    • LAMEAの市場規模・予測:投与経路別
    • LAMEAの市場規模・予測:流通チャネル別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Alkermes, Inc.
  • apotex inc.
  • Aurobindo Pharma Ltd
  • Eli Lilly and Company
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Torrent Group
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Viatris
図表

LIST OF TABLES

  • TABLE 1. GLOBAL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. OLANZAPINE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. OLANZAPINE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. GLOBAL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. OLANZAPINE MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. OLANZAPINE MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. OLANZAPINE MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. OLANZAPINE MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. OLANZAPINE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. NORTH AMERICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. NORTH AMERICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. NORTH AMERICA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. U.S. OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. U.S. OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. CANADA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. CANADA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. MEXICO OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. MEXICO OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. EUROPE OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. GERMANY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. GERMANY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. GERMANY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. FRANCE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. FRANCE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. FRANCE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. UK OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. UK OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ITALY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. ITALY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ITALY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. SPAIN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. SPAIN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SPAIN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. REST OF EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. REST OF EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. REST OF EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. ASIA-PACIFIC OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. JAPAN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. JAPAN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. JAPAN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. CHINA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. CHINA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. CHINA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. INDIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. INDIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. INDIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. AUSTRALIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. AUSTRALIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. AUSTRALIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. SOUTH KOREA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. SOUTH KOREA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. SOUTH KOREA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. LAMEA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. BRAZIL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. BRAZIL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. BRAZIL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SAUDI ARABIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SAUDI ARABIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SAUDI ARABIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH AFRICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SOUTH AFRICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SOUTH AFRICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. REST OF LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94.ALKERMES, INC.: COMPANY SNAPSHOT
  • TABLE 95.ALKERMES, INC.: OPERATING SEGMENTS
  • TABLE 96.ALKERMES, INC.: PRODUCT PORTFOLIO
  • TABLE 97.ALKERMES, INC.: NET SALES
  • TABLE 98.ALKERMES, INC.: KEY STRATERGIES
  • TABLE 99.APOTEX INC.: COMPANY SNAPSHOT
  • TABLE 100.APOTEX INC.: OPERATING SEGMENTS
  • TABLE 101.APOTEX INC.: PRODUCT PORTFOLIO
  • TABLE 102.APOTEX INC.: NET SALES
  • TABLE 103.APOTEX INC.: KEY STRATERGIES
  • TABLE 104.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
  • TABLE 105.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
  • TABLE 106.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
  • TABLE 107.AUROBINDO PHARMA LTD: NET SALES
  • TABLE 108.AUROBINDO PHARMA LTD: KEY STRATERGIES
  • TABLE 109.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 110.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 111.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 112.ELI LILLY AND COMPANY: NET SALES
  • TABLE 113.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 114.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 115.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 116.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 117.DR. REDDY'S LABORATORIES LTD.: NET SALES
  • TABLE 118.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 119.SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 120.SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
  • TABLE 121.SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 122.SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
  • TABLE 123.SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 124.TORRENT GROUP: COMPANY SNAPSHOT
  • TABLE 125.TORRENT GROUP: OPERATING SEGMENTS
  • TABLE 126.TORRENT GROUP: PRODUCT PORTFOLIO
  • TABLE 127.TORRENT GROUP: NET SALES
  • TABLE 128.TORRENT GROUP: KEY STRATERGIES
  • TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
  • TABLE 131.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 132.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
  • TABLE 133.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 134.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 135.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 136.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 137.NOVARTIS AG: NET SALES
  • TABLE 138.NOVARTIS AG: KEY STRATERGIES
  • TABLE 139.VIATRIS: COMPANY SNAPSHOT
  • TABLE 140.VIATRIS: OPERATING SEGMENTS
  • TABLE 141.VIATRIS: PRODUCT PORTFOLIO
  • TABLE 142.VIATRIS: NET SALES
  • TABLE 143.VIATRIS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.OLANZAPINE MARKET SEGMENTATION
  • FIGURE 2.OLANZAPINE MARKET,2021-2031
  • FIGURE 3.OLANZAPINE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.OLANZAPINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.OLANZAPINE MARKET,BY APPLICATION,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SCHIZOPHRENIA OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BIPOLAR DISORDER OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 16.OLANZAPINE MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PARENTERAL OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 19.OLANZAPINE MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 23.OLANZAPINE MARKET BY REGION,2021
  • FIGURE 24.U.S. OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 25.CANADA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 26.MEXICO OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 27.GERMANY OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 28.FRANCE OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 29.UK OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 30.ITALY OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 31.SPAIN OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 32.REST OF EUROPE OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 33.JAPAN OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 34.CHINA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 35.INDIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 37.SOUTH KOREA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF ASIA-PACIFIC OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 39.BRAZIL OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 40.SAUDI ARABIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF LAMEA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47.COMPETITIVE DASHBOARD
  • FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 49.ALKERMES, INC..: NET SALES ($MILLION)
  • FIGURE 50.APOTEX INC..: NET SALES ($MILLION)
  • FIGURE 51.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
  • FIGURE 52.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
  • FIGURE 53.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
  • FIGURE 54.SUN PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 55.TORRENT GROUP.: NET SALES ($MILLION)
  • FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 57.NOVARTIS AG.: NET SALES ($MILLION)
  • FIGURE 58.VIATRIS.: NET SALES ($MILLION)
目次
Product Code: A15452

Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder. It is available in the form of a tablet, injectable, and a disintegrating tablet. It balances dopamine and serotonin to enhance cognition, mood, and behavior. Olanzapine is used to treat the symptoms of schizophrenia, which is a mental condition that causes disturbed or strange thinking, loss of interest in life, and strong or inappropriate emotions, in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder, which is a manic-depressive disorder, a condition that produces episodes of mania, sadness, and other abnormal moods, in adults and adolescents 13 years of age and older.

World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.

The growth of global olanzapine market is majorly driven by rise in prevalence of schizophrenia globally. For instance, in January 2022, according to World Health Organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) globally. In addition, increase in cases of Hospital Acquired Infections (HAI), owing to lack of sanitation and preventive measures, is a major factor responsible for the market growth. Furthermore, rise in the number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, high cost of olanzapine and side effects of olanzapine hinder the market growth. Conversely, rise in product approvals for olanzapine in market by key players and high growth potential in developing economies are anticipated to provide lucrative opportunities to the market players. For instance, in June 2021, Alkermes plc., a global biopharmaceutical company, received U.S. Food and Drug Administration (FDA) for its LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

The olanzapine market is segmented into application, route of administration, distribution channel, and region. On the basis of application, the market is segregated into schizophrenia, bipolar disorders, and others. By route of administration, the market is segmented into oral and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global olanzapine market are Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Bipolar Disorder
  • Others
  • Schizophrenia

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Alkermes, Inc.
    • apotex inc.
    • Aurobindo Pharma Ltd
    • Eli Lilly and Company
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Torrent Group
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Viatris

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Schizophrenia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Bipolar Disorder
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oral
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Parenteral
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: OLANZAPINE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Application
    • 7.2.3 North America Market size and forecast, by Route of Administration
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Application
    • 7.3.3 Europe Market size and forecast, by Route of Administration
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Application
    • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Application
    • 7.5.3 LAMEA Market size and forecast, by Route of Administration
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by Route of Administration
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Alkermes, Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 apotex inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Aurobindo Pharma Ltd
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Dr. Reddy's Laboratories Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Sun Pharmaceutical Industries Limited
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Torrent Group
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Teva Pharmaceutical Industries Limited
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Novartis AG
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Viatris
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments